Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Head-to-head study of the osteoporosis agents used bone mineral density as primary endpoint; competitors Sanofi-Aventis/P&G maintain fracture is appropriate efficacy measure. Merck study authors say 50,000 patients would be needed to power a trial for fracture risk.